Literature DB >> 34987197

Retinoblastoma and vision.

Omar Warda1, Zishan Naeem1, Kelsey A Roelofs1,2, Mandeep S Sagoo1,2,3, M Ashwin Reddy4,5.   

Abstract

The assessment of vision has a growing importance in the management of retinoblastoma in the era of globe-conserving therapy, both prior to and after treatment. As survival rates approach 98-99% and globe salvage rates reach ever-higher levels, it is important to provide families with information regarding the visual outcomes of different treatments. We present an overview of the role of vision in determining the treatment given and the impact of complications of treatment. We also discuss screening and treatment strategies that can be used to maximise vision.
© 2021. The Author(s).

Entities:  

Year:  2022        PMID: 34987197     DOI: 10.1038/s41433-021-01845-y

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  80 in total

1.  Attentional processes in young children with congenital visual impairment.

Authors:  Valerie Tadić; Linda Pring; Naomi Dale
Journal:  Br J Dev Psychol       Date:  2009-06

2.  Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma.

Authors:  Carlos Bianciotto; Carol L Shields; Juan C Iturralde; Ahmet Sarici; Pascal Jabbour; Jerry A Shields
Journal:  Ophthalmology       Date:  2011-12-02       Impact factor: 12.079

Review 3.  Treatment of Retinoblastoma in 2015: Agreement and Disagreement.

Authors:  David H Abramson; Carol L Shields; Francis L Munier; Guillermo L Chantada
Journal:  JAMA Ophthalmol       Date:  2015-11       Impact factor: 7.389

Review 4.  The management of retinoblastoma.

Authors:  Ido D Fabian; Zerrin Onadim; Esin Karaa; Catriona Duncan; Tanzina Chowdhury; Irene Scheimberg; Shin-Ichi Ohnuma; M Ashwin Reddy; Mandeep S Sagoo
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

5.  Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk.

Authors:  F L Wong; J D Boice; D H Abramson; R E Tarone; R A Kleinerman; M Stovall; M B Goldman; J M Seddon; N Tarbell; J F Fraumeni; F P Li
Journal:  JAMA       Date:  1997-10-15       Impact factor: 56.272

6.  Developmental outcome, including setback, in young children with severe visual impairment.

Authors:  Naomi Dale; Patricia Sonksen
Journal:  Dev Med Child Neurol       Date:  2002-09       Impact factor: 5.449

7.  Visual outcomes following intraophthalmic artery melphalan for patients with refractory retinoblastoma and age appropriate vision.

Authors:  Maria Tsimpida; Dorothy A Thompson; Alki Liasis; Vicki Smith; Judith E Kingston; Mandeep S Sagoo; M Ashwin Reddy
Journal:  Br J Ophthalmol       Date:  2013-09-13       Impact factor: 4.638

8.  Craniofacial second primary tumors in patients with germline retinoblastoma previously treated with external beam radiotherapy: A retrospective institutional analysis.

Authors:  Irene Jiménez; Marick Laé; Marie-Laure Tanguy; Alexia Savignoni; Marion Gauthier-Villars; Laurence Desjardins; Nathalie Cassoux; Rémi Dendale; Joseph Rodriguez; François Doz; Hervé J Brisse; Isabelle Aerts
Journal:  Pediatr Blood Cancer       Date:  2020-01-06       Impact factor: 3.167

9.  Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma.

Authors:  Scott E Brodie; Y Pierre Gobin; Ira J Dunkel; Jonathan W Kim; David H Abramson
Journal:  Doc Ophthalmol       Date:  2009-01-25       Impact factor: 2.379

10.  Health-related quality of life of child and adolescent retinoblastoma survivors in the Netherlands.

Authors:  Jennifer van Dijk; Jaap Huisman; Annette C Moll; Antoinette Y N Schouten-van Meeteren; Pieter D Bezemer; Peter J Ringens; Peggy T Cohen-Kettenis; Saskia M Imhof
Journal:  Health Qual Life Outcomes       Date:  2007-12-03       Impact factor: 3.186

View more
  1 in total

1.  Myopia and Other Visual Disorders in Children.

Authors:  Cristina Alvarez-Peregrina; Clara Martinez-Perez; Miguel Ángel Sánchez-Tena
Journal:  Int J Environ Res Public Health       Date:  2022-07-22       Impact factor: 4.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.